31 March 2021 - Late treatment study
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (preprint 3/31/2021) (Peer Reviewed)
PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combination of both.
|
risk of death, 15.4% lower, RR 0.85, p = 0.08, treatment 527, control 527, odds ratio converted to relative risk, aspirin only, control prevalence approximated with treatment prevalence, propensity score matching.
|
|
risk of death, 37.3% lower, RR 0.63, p = 0.001, treatment 305, control 305, odds ratio converted to relative risk, famotidine and aspirin, control prevalence approximated with treatment prevalence, propensity score matching.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Mura et al., 3/31/2021, retrospective, database analysis, multiple countries, multiple regions, peer-reviewed, 6 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.